Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index; 45 of the 232 sources its claims cite were checked for support.

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview

Open access

Abstract

The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics that have implications for medication selection, administration interval, and injection site. This review outlines key differences in drug formulations and pharmacokinetics among LAI antipsychotics. A systematic search of the PubMed database was conducted to identify physical and formulation properties and pharmacokinetic data of commercially available LAI antipsychotics, including flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate, risperidone microspheres, and risperidone polymeric microspheres. Additional information was obtained from package inserts and product monographs. Relevant data on drug properties, administration details, pharmacokinetic parameters, and oral dose equivalencies of LAI antipsychotics are summarized. Based on our analysis, formulation characteristics (e.g., vehicle medium) and administration characteristics (e.g., injection site) can affect rate of absorption and adverse effects and may factor into whether oral supplementation or an additional injection is needed. Dose adjustments may be necessary based on potential drug-drug interactions, and approximate dose equivalence with oral formulations can help inform titration when switching from oral to LAI formulations. Clinicians administering LAI antipsychotics should consider these formulation and pharmacokinetic factors to maximize clinical impact and to adjust to an individual patient's needs and treatment goals.

Overview

CoChat Summary

TL;DR

This overview summarizes formulation and pharmacokinetic characteristics of commercially available long-acting injectable (LAI) antipsychotics for schizophrenia, drawing on a systematic PubMed search plus package inserts and product monographs. It emphasizes that LAI absorption, half-life, injection site, interactions, and oral dose equivalence differ substantially and should guide drug selection, dosing, and administration.

Key findings

  • LAI antipsychotics generally show “flip-flop” kinetics: absorption is slower than elimination, so time to steady state is driven by absorption, and steady state typically occurs after 4–5 half-lives. Reported apparent half-lives vary widely, e.g., fluphenazine decanoate 7–10 days, haloperidol decanoate 21 days, aripiprazole monohydrate 29.9–46.5 days, aripiprazole lauroxil 53.9–57.2 days, paliperidone palmitate every 3 months 84–95 days (deltoid) and 118–139 days (gluteal), risperidone microspheres 3–6 days, and risperidone polymer total active moiety 8–9 days.
  • Time to peak concentration also differs by formulation and site: flupentixol decanoate 4–10 days, haloperidol decanoate 3–9 days, aripiprazole lauroxil 41 days, paliperidone palmitate once monthly 13 days, paliperidone palmitate every 3 months 30–33 days, risperidone microspheres ~30 days, and risperidone polymer 4–6 h.
  • Formulation and administration factors can affect absorption and adverse effects; for example, aripiprazole monohydrate median tmax is 4 days after deltoid injection versus 5–7 days after gluteal injection, and paliperidone palmitate every 3 months has a longer apparent half-life after gluteal than deltoid injection.
  • Drug–drug interactions and oral dose equivalencies are clinically relevant: CYP2D6/CYP3A4 inhibitors or inducers may require dose adjustments for several LAIs, and examples include 15–20 mg oral aripiprazole daily corresponding to 400 mg aripiprazole monohydrate every 4 weeks, and 3 mg or 4 mg oral risperidone daily corresponding to 90 mg or 120 mg risperidone polymer, respectively.

Methods

  • Narrative overview with a systematic literature search of PubMed performed on 17 October 2018 using terms: (Long-acting OR depot OR injectable) AND (antipsychotic* OR neuroleptic*) AND (pharmacokinetic* OR PK), limited to English; a second search was performed on 11 September 2020 for articles published after 18 October 2018.
  • The initial search returned 327 English-language articles; after manual screening, 52 abstracts with relevant LAI pharmacokinetic data were identified, plus data from 12 product package inserts and/or monographs; the second search identified three relevant abstracts.
  • The review summarizes formulation properties, pharmacokinetic characteristics, administration details, and oral dose equivalencies for commercially available LAIs including flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate, risperidone microspheres, and risperidone polymeric microspheres.

Limitations

  • The paper states that LAI antipsychotics have fewer available dosage strengths than oral formulations; for example, PP1M, PP3M, and aripiprazole lauroxil have five, four, and three available oral dose equivalents, respectively, whereas olanzapine pamoate and risperidone polymer have two and aripiprazole monohydrate has one.
  • The paper states that long half-lives may prolong adverse effects, so tolerability should be assessed with shorter-acting preparations before longer-acting formulations are initiated; it also notes that no guidance is provided for missed doses of some first-generation LAIs and risperidone microspheres.
  • The paper cautions that a comparison of aripiprazole plasma concentrations between aripiprazole monohydrate 400 mg and aripiprazole lauroxil 882 mg should be interpreted cautiously because data inputs came from different time points and different steady-state concentrations (average vs. minimum). Evident from the text: this is an overview relying largely on published studies, package inserts, and product monographs rather than a formal meta-analysis with patient-level data or risk-of-bias assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40263-020-00779-5

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flip-flop pharmacokinetics. A Equation used to calculate concentration at time t. B Representative concentration–time curves. Cmax maximum concentration, Cp plasma concentration at time t, F bioavailability, kfast absorption rate constant for an oral drug and elimination rate constant for an LAI, kslow absorption rate constant for an LAI and elimination rate constant for an oral drug, LAI long-acting injectable, t time, tmax time to maximum concentration, Vd volume of distribution
Fig. 1 Flip-flop pharmacokinetics. A Equation used to calculate concentration at time t. B Representative concentration–time curves. Cmax maximum concentration, Cp plasma concentration at time t, F bioavailability, kfast absorption rate constant for an oral drug and elimination rate constant for an LAI, kslow absorption rate constant for an LAI and elimination rate constant for an oral drug, LAI long-acting injectable, t time, tmax time to maximum concentration, Vd volume of distributionCC BY-NC · PubMed Central
Fig. 2 Peak-to-trough plasma concentration ratios of oral and long-acting injectable antipsychotics at steady state [36, 118–121]. AL aripiprazole lauroxil, AM aripiprazole monohydrate, ER extended release, LAI long-acting injectable, PP1M paliperidone palmitate once monthly, PP3M paliperidone palmitate every 3 months, qxw every x weeks, RLAI-MS risperidone long-acting injection microspheres
Fig. 2 Peak-to-trough plasma concentration ratios of oral and long-acting injectable antipsychotics at steady state [36, 118–121]. AL aripiprazole lauroxil, AM aripiprazole monohydrate, ER extended release, LAI long-acting injectable, PP1M paliperidone palmitate once monthly, PP3M paliperidone palmitate every 3 months, qxw every x weeks, RLAI-MS risperidone long-acting injection microspheresCC BY-NC · PubMed Central
Fig. 3 PRISMA flow diagram. LAI long-acting injectable, PK pharmacokinetics, PI package insert
Fig. 3 PRISMA flow diagram. LAI long-acting injectable, PK pharmacokinetics, PI package insertCC BY-NC · PubMed Central

Verification

Claims the paper makes

36 Valid · 4 Not valid · 133 Not checked · 29 Own results and interpretations

69 more claims · 9 with their cited sources checked

Create a free account to see all 202 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 65
  • It may state two separate claims as one. 82

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 121 references

Research works printed but not linked: 1

  1. Gelenberg AJ. Significant greater loss of medication from the injection site when fluphenazine (Prolixin) decanoate was injected intramuscularly as contrasted with subcutaneously. J Clin Psychiatry. 1987;48(10):425.

Cited by

See all 205

Metadata

Authors
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R.
Affiliations
  • Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
  • Janssen Scientific Affairs (United States) (US)
  • The University of Texas at San Antonio Health Science Center (US)
Corresponding author
Saklad, Stephen R.
Venue
CNS Drugs
Published
2021-01
Volume
35
Issue
1
Pages
39-59
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W3124121244
Cited by
205
References
121
Citations by year
2026: 44 · 2025: 53 · 2024: 36 · 2023: 41 · 2022: 20 · 2021: 11
FWCI
4.87
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Janssen Research and Development
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
long-acting injectable antipsychotics, schizophrenia, pharmacokinetics, drug formulation, fluphenazine decanoate, haloperidol decanoate, aripiprazole, olanzapine pamoate, paliperidone palmitate, injection site, drug-drug interactions, dose equivalence, oral supplementation, medication adherence
MeSH terms
Administration, Oral, Delayed-Action Preparations, Dose-Response Relationship, Drug, Humans, Injections, Schizophrenia, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. https://app.cochat.ai/papers/10.1007/s40263-020-00779-5
The paper
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021). Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs. https://doi.org/10.1007/s40263-020-00779-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.